A forum for researchers, students and applicants in the field of cyclodextrin technology
Strategic drug repurposing in combination with rapid testing of established molecular targets could provide a pause in disease progression and
Cyclo Therapeutics, Inc., a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Cyclo Therapeutics, Inc. a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Cyclo Therapeutics, Inc. formerly CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment of disease, announced
CTD Holdings, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical
In the recent two weeks, Cyclolab had the pleasure to welcome two prominent pioneers of cyclodextrin research, Prof. Loftsson from
A paper has just come out in Macromolecular Rapid Communications highlighting the potential benefits of cyclodextrin-based macromolecular systems as cholesterol-mopping
If you are following advances in the re-discovery of cyclodextrins as APIs, there is quite a race among the candidates
Clearly, understanding the mechanism of action for cyclodextrins and consequently finding the most appropriate canditate for the treatment of Niemann
